Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v2.4.0.8
Condensed Consolidated Balance Sheets (Unaudited) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 119,061 [1] $ 27,361 [1]
Marketable securities 50,027 [1] 0 [1]
Accounts receivable, net 22,227 [1] 21,162 [1]
Inventory, net 19,778 [1] 22,261 [1]
Prepaid expenses and other current assets 19,023 [1] 7,873 [1]
Total current assets 230,116 [1] 78,657 [1]
Property, plant, equipment, and investment properties, net 16,577 [1] 16,526 [1]
Intangible assets, net 79,775 [1] 84,238 [1]
In-process research and development 203,052 [1] 11,546 [1]
Goodwill 82,086 [1] 80,450 [1]
Investments, net 26,690 [1] 15,636 [1]
Other assets 2,784 [1] 2,777 [1]
Total assets 641,080 [1] 289,830 [1]
Current liabilities:    
Accounts payable 11,646 [1] 10,200 [1]
Accrued expenses 31,045 [1] 24,656 [1]
Current portion of lines of credit and notes payable 16,778 [1] 17,526 [1]
Total current liabilities 59,469 [1] 52,382 [1]
3.00% convertible senior notes, net of discount and estimated fair value of embedded derivatives 188,524 [1] 0 [1]
Other long-term liabilities, principally contingent consideration and deferred tax liabilities 80,603 [1] 34,168 [1]
Total long-term liabilities 269,127 [1] 34,168 [1]
Total liabilities 328,596 [1] 86,550 [1]
Commitments and contingencies:    [1]    [1]
Series D Preferred Stock - $0.01 par value, 2,000,000 shares authorized; no shares issued or outstanding at June 30, 2013 and 1,129,032 shares issued and outstanding (liquidation value of $30,595) at December 31, 2012 0 [1] 24,386 [1]
Equity:    
Common Stock - $0.01 par value, 500,000,000 shares authorized; 339,045,029 and 305,560,763 shares issued at June 30, 2013 and December 31, 2012, respectively 3,391 [1] 3,056 [1]
Treasury Stock - 2,293,056 shares at both June 30, 2013 and December 31, 2012 (7,457) [1] (7,457) [1]
Additional paid-in capital 742,097 [1] 565,201 [1]
Accumulated other comprehensive income 2,830 [1] 7,356 [1]
Accumulated deficit (426,379) [1] (388,770) [1]
Total shareholders’ equity 314,482 [1] 179,386 [1]
Noncontrolling interests (1,998) [1] (492) [1]
Total equity 312,484 [1] 178,894 [1]
Total liabilities, Series D Preferred Stock, and equity 641,080 [1] 289,830 [1]
Series A Preferred Stock
   
Equity:    
Preferred Stock 0 [1] 0 [1]
Series C Preferred Stock
   
Equity:    
Preferred Stock $ 0 [1] $ 0 [1]
[1] As of June 30, 2013 and December 31, 2012, total assets include $6.0 million and $5.6 million, respectively, and total liabilities include $7.8 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities are those as to which there is no recourse against us. Refer to Note 5.